Sigma 1 receptor mediated HMGB1 expression in spinal cord is involved in the development of diabetic neuropathic pain

Wang, Xiaolei; Feng, Chang; Qiao, Yong; Zhao, Xin

doi:10.1016/j.neulet.2018.02.002

Cited by 17 publications

(21 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, STZ treatment induces Sigma-1R and HMGB1 expression in DRG, with increased tactile allodynia and thermal hyperalgesia in rat models [112]. Conversely, knockdown rats for Sigma-1R show a modest tactile allodynia and thermal hyperalgesia in absence of increased cytoplasmic levels of HMGB1 levels [112]. The same result has been demonstrated after HMGB1 inhibition in spinal cord.…”

Section: Hmgb1 and Diabetic Neuropathymentioning

confidence: 71%

“…The same result has been demonstrated after HMGB1 inhibition in spinal cord. These findings suggest a role of Sigma-1R in promoting HMGB1 expression [112]. Table 5.…”

Section: Hmgb1 and Diabetic Neuropathymentioning

confidence: 83%

“…There are also implicated down-regulation of growth factors, up-regulation of neurotrophin 3, autophagic pathway and wnt pathway [110]. Few studies have analyzed the linkage between HMGB1 and DNr [112][113][114][115][116] (Table 5), starting from previous data that demonstrated the role of HMGB1 in nervous system [117][118][119]. In fact, as mentioned above, HMGB1 is involved in central ischemic damage, being released into the extracellular space after ischemic insult where it promotes neuroinflammation [117].…”

Section: Hmgb1 and Diabetic Neuropathymentioning

confidence: 99%

“…The expression of HMGB1 in neuropathic pain seems also correlated with Sigma-1 receptor (Sigma-1R), a receptor involved in nociception. In fact, STZ treatment induces Sigma-1R and HMGB1 expression in DRG, with increased tactile allodynia and thermal hyperalgesia in rat models [112]. Conversely, knockdown rats for Sigma-1R show a modest tactile allodynia and thermal hyperalgesia in absence of increased cytoplasmic levels of HMGB1 levels [112].…”

Section: Hmgb1 and Diabetic Neuropathymentioning

confidence: 99%

See 3 more Smart Citations

High Mobility Group Box-1 and Diabetes Mellitus Complications: State of the Art and Future Perspectives

Biscetti

Rando

Nardella

et al. 2019

IJMS

View full text Add to dashboard Cite

Diabetes mellitus (DM) is an endemic disease, with growing health and social costs. The complications of diabetes can affect potentially all parts of the human body, from the heart to the kidneys, peripheral and central nervous system, and the vascular bed. Although many mechanisms have been studied, not all players responsible for these complications have been defined yet. High Mobility Group Box-1 (HMGB1) is a non-histone nuclear protein that has been implicated in many pathological processes, from sepsis to ischemia. The purpose of this review is to take stock of all the most recent data available on the role of HMGB1 in the complications of DM.

show abstract

Section: Hmgb1 and Diabetic Neuropathymentioning

confidence: 71%

“…The same result has been demonstrated after HMGB1 inhibition in spinal cord. These findings suggest a role of Sigma-1R in promoting HMGB1 expression [112]. Table 5.…”

Section: Hmgb1 and Diabetic Neuropathymentioning

confidence: 83%

Section: Hmgb1 and Diabetic Neuropathymentioning

confidence: 99%

Section: Hmgb1 and Diabetic Neuropathymentioning

confidence: 99%

See 2 more Smart Citations

High Mobility Group Box-1 and Diabetes Mellitus Complications: State of the Art and Future Perspectives

Biscetti

Rando

Nardella

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…1 receptor-mediated HMGB1 expression in the spinal cord was involved in the development of diabetic neuropathic pain. Another result suggested that 1 receptor-mediated enhancement of HMGB1 expression in the DRG was critical for the development of peripheral neuropathy in type 1 diabetes (Wang et al, 2018b). Glycyrrhizin could reduce hyperglycemiainduced HMGB1 activation in ZDF rats and contribute to the progression of DN (Thakur et al, 2017).…”

Section: Glycyrrhizinmentioning

confidence: 99%

Antidiabetic Potential of Flavonoids from Traditional Chinese Medicine: A Review

Bai

et al. 2019

Am. J. Chin. Med.

155

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a group of metabolic disorders in which high blood sugar levels occur over a prolonged period. Approximately 4% of the global population is affected by DM. Western medical treatment methods for diabetes including injection or oral hypoglycemic drugs have some toxic or side effects, economic pressures, and so on. Many researchers turn to discover new drugs from natural products or Traditional Chinese Medicine (TCM). Flavonoids are widely distributed in plants, and many studies have shown that flavonoids possess antidiabetic properties, exhibiting not only well-recognized antidiabetic and hypoglycemic activities but also activity in the treatment of diabetic complications. In this review, we systematically summarized anti-diabetic flavonoid compounds based on structure classification by examining the PubMed, Springer Link, Web of Science, and CNKI databases. There are 13 flavonoid compounds listed which have been studied extensively and have antidiabetic features respectively. Apigenin, baicalein, and catechin mainly reduces blood glucose via anti-oxidation; hesperidin is good for diabetic neuropathy; glycyrrhiza flavonoids have a significant effect on gestational DM; quercetin takes advantage of crossing the blood–brain barrier and improving renal function. Some compounds have protective and preventive effects on diabetic complications, such as kaempferol and puerarin which are beneficial to cardiomyopathy; myricetin has therapeutic potential in the treatment of DN; dihydromyricetin might improve CI. It is a pity or might be a pointcut that most studies remain in the animal experimental stage, and further investigation should be carried out.

show abstract

Redefining distal symmetrical polyneuropathy features in type 1 diabetes: a systematic review

Galosi

Michael

et al. 2021

Acta Diabetol

View full text Add to dashboard Cite

Diabetic neuropathy is among the most frequent complications of both type 1 (T1DM) and type 2 diabetes (T2DM) and commonly manifests as a distal symmetrical polyneuropathy (DSPN). Despite evidence that T1DM- and T2DM-related DSPN are separate entities, most of our knowledge on diabetic DSPN derives from studies focused on type 2 diabetes. This systematic review provides an overview of current evidence on DSPN in T1DM, including its epidemiological, pathophysiological and clinical features, along with principal diagnostic tests findings. This review included 182 clinical and preclinical studies. The results indicate that DSPN is a less frequent complication in T1DM compared with T2DM and that distinctive pathophysiological mechanisms underlie T1DM-related DSPN development, with hyperglycemia as a major determinant. T1DM-related DSPN more frequently manifests with non-painful than painful symptoms, with lower neuropathic pain prevalence compared with T2DM-associated DSPN. The overt clinical picture seems characterized by a higher prevalence of large fiber-related clinical signs (e.g., ankle reflexes reduction and vibration hypoesthesia) and to a lesser extent small fiber damage (e.g., thermal or pinprick hypoesthesia). These findings as a whole suggest that large fibers impairment plays a dominant role in the clinical picture of symptomatic T1DM-related DSPN. Nevertheless, small fiber diagnostic testing shows high diagnostic accuracy in detecting early nerve damage and may be an appropriate diagnostic tool for disease monitoring and screening.

show abstract

Sigma 1 receptor mediated HMGB1 expression in spinal cord is involved in the development of diabetic neuropathic pain

Cited by 17 publications

References 33 publications

High Mobility Group Box-1 and Diabetes Mellitus Complications: State of the Art and Future Perspectives

High Mobility Group Box-1 and Diabetes Mellitus Complications: State of the Art and Future Perspectives

Antidiabetic Potential of Flavonoids from Traditional Chinese Medicine: A Review

Redefining distal symmetrical polyneuropathy features in type 1 diabetes: a systematic review

Contact Info

Product

Resources

About